Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide in type 2 diabetes patients inadequately controlled on metformin ± sulfonylurea
CTR20200114Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Feb 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of efpeglenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Feb 2020; status: terminated.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20200114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200114.